JPS63179812A - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JPS63179812A JPS63179812A JP62013062A JP1306287A JPS63179812A JP S63179812 A JPS63179812 A JP S63179812A JP 62013062 A JP62013062 A JP 62013062A JP 1306287 A JP1306287 A JP 1306287A JP S63179812 A JPS63179812 A JP S63179812A
- Authority
- JP
- Japan
- Prior art keywords
- propolis
- sebum
- remedy
- skin
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- 241000241413 Propolis Species 0.000 claims abstract description 28
- 229940069949 propolis Drugs 0.000 claims abstract description 28
- 210000002374 sebum Anatomy 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 239000002904 solvent Substances 0.000 abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 6
- 230000028327 secretion Effects 0.000 abstract description 6
- 208000017520 skin disease Diseases 0.000 abstract description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000011259 mixed solution Substances 0.000 abstract description 3
- 201000004624 Dermatitis Diseases 0.000 abstract description 2
- 241000257303 Hymenoptera Species 0.000 abstract description 2
- 238000004821 distillation Methods 0.000 abstract description 2
- 230000002441 reversible effect Effects 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract 1
- 239000012466 permeate Substances 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 239000012261 resinous substance Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- -1 aromatic alcohols Chemical class 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 229910016459 AlB2 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 101000693961 Trachemys scripta 68 kDa serum albumin Proteins 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000009341 apiculture Methods 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 1
- 229960003070 tioxolone Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229950010121 ufenamate Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は皮膚外用剤に関する。更に詳しくは、プロポリ
スの抽出物を有効成分として含有する外用剤に関するも
ので、皮脂の分泌過剰によっておこる皮膚炎、酒さ等の
脂漏性疾患で温和な効果を示す皮膚疾患治療剤である。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to an external preparation for skin. More specifically, the present invention relates to an external preparation containing an extract of propolis as an active ingredient, and is a skin disease treatment agent that shows mild effects on seborrheic diseases such as dermatitis and rosacea caused by excessive secretion of sebum.
[従来の技術]
プロポリスは古くから伝承的民間薬として利用されてお
り、近年東欧諸国を中心にその機能、作用が、解明され
つつある。抗菌作用、止血作用、痩痕化作用、抗炎症作
用、抗酸化作用、局所麻酔作用、腫瘍増殖抑制作用等に
ついて多くの報告がある。プロポリスの成分はフラボン
類、フラバノン類、芳香族アルコール、芳香族アルデヒ
ド、クマリン等が主なもので、これらの組成、含有量等
はプロポリスの産地によって異なり、作用も差異がある
と言われている。[Prior Art] Propolis has been used as a traditional folk medicine since ancient times, and its functions and effects have recently been elucidated mainly in Eastern European countries. There are many reports on its antibacterial, hemostatic, scarring, anti-inflammatory, antioxidant, local anesthetic, and tumor growth inhibitory effects. The main components of propolis are flavones, flavanones, aromatic alcohols, aromatic aldehydes, coumarins, etc. The composition and content of these substances vary depending on where propolis is produced, and it is said that their effects also differ. .
一方、今日まで特異的に皮脂分泌抑制を示し、それら以
外の器官に影響しないような化合物は知られていない。On the other hand, to date, no compound has been known that specifically inhibits sebum secretion and does not affect other organs.
経口投与用に皮脂抑制剤シブロチロンアセテートがある
が、経口投与は局所施用よりも副作用が大きいことが多
い。また、その抗アンドロゲン性のために、シブロチロ
ンアセテートは女性にのみしか用いることができない。The sebum suppressant sibrothyrone acetate is available for oral administration, but oral administration often has greater side effects than topical application. Also, due to its anti-androgenic properties, sibrothyrone acetate can only be used by women.
[発明が解決しようとする問題点]
本発明者らは、特異的に皮脂分泌抑制を示し、それら以
外の器官に影響しないような化合物を研究していたとこ
ろ、プロポリスの抽出物を有効成分として配合してなる
外用剤が、この目的を達成できることを見いだして、本
発明を完成した。[Problems to be Solved by the Invention] The present inventors were researching compounds that specifically inhibit sebum secretion and do not affect other organs, and discovered that propolis extract was used as an active ingredient. The present invention was completed based on the discovery that an external preparation prepared by the above methods can achieve this objective.
[問題点を解決するための手段]
すなわち本発明は、プロポリスの抽出物を有効成分とし
て含有することを特徴とする皮脂外用剤である。[Means for Solving the Problems] That is, the present invention is a sebum external preparation characterized by containing an extract of propolis as an active ingredient.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
本発明に用いられるプロポリス(propo l i
s)は、前述の通り、ミツバチによって植物から採取さ
れるヤニ状の物質であり、蜂ヤニとも呼ばれている。Propolis used in the present invention
As mentioned above, s) is a tar-like substance collected from plants by bees, and is also called bee tar.
一般的には養蜂の際に巣箱の巣枠や隙間に多量に付着す
るのでこれをかきとって採集される。Generally, during beekeeping, large amounts of bee adhere to the frames and crevices of hives, so they are collected by scraping them off.
上記のプロポリスからの抽出液または抽出物は以下の様
にして製造される。プロポリスを水と親水性溶媒の混液
あるいは親水性溶媒に浸漬して抽出しく一般的にはプロ
ポリスの10重量倍程度の抽出液を用いる)、プロポリ
ス抽出液を得る。親水性溶媒としては、例えばメタノー
ル、エタノール等のアルコール及びアセトンが挙げられ
る。プロポリス抽出液から蒸留その他の方法で溶媒を留
去することにより、プロポリス抽出物を得る。配合量と
して抽出物(抽出溶媒を留去した残分)として全組成中
に概ね0.001%(重量%)以上配合する。配合量の
上限は特に限定するものではないが着色等の商品価値の
観点からプロポリスおよびその抽出物の配合量は、乾燥
残部として合計で約10%まで配合するのが好ましい。The above-mentioned extract or extract from propolis is produced as follows. Propolis is extracted by immersing it in a mixture of water and a hydrophilic solvent or in a hydrophilic solvent (generally, an extract having an amount of about 10 times the weight of propolis is used) to obtain a propolis extract. Examples of the hydrophilic solvent include alcohols such as methanol and ethanol, and acetone. A propolis extract is obtained by removing the solvent from the propolis extract by distillation or other methods. The amount of the extract (residue after distilling off the extraction solvent) is approximately 0.001% (wt%) or more in the entire composition. Although the upper limit of the blending amount is not particularly limited, from the viewpoint of commercial value such as coloring, it is preferable that the blending amount of propolis and its extract is up to about 10% in total as the dry residue.
本発明の皮膚外用剤には、プロポリス抽出物のほかにイ
オウ、ヒノキチオール、トリクロサン、トリクロロカル
バニリド、クロルヘキシジン塩酸塩、クロルヘキシジン
グルコン酸塩、ハロカルパン、クロロフエネシン、塩化
ベンゼトニウム、塩化ベンザルコニウム、塩化リゾチー
ム、塩酸アルキルジアミノエチルグリシン、イソプロピ
ルメチルフェノール、安息香酸、感光素201号、チモ
ール、ヘキサクロロフェン、ベルベリン、チオキソロン
などの抗菌剤、またビタミンAlB2、B6、E5ビオ
チン、ニコチン酸等のビタミン剤やサリチル酸、レゾル
シン等の角質剥離剤、クリチルレチン酸、グリチルリチ
ン酸、アラントイン、イプシロンアミノカプロン酸、フ
ルフェナム酸ブチル、アズレン、カンファー、塩化亜鉛
、亜鉛華、メントール、インドメタシン、イブプロフェ
ンピコノール、メフェナム酸ならびにそれらの誘導体等
の抗炎症剤、さらに亜鉛およびその化合物、乳酸および
性状によっても異なるが、油分、界面活性剤、水、エタ
ノール、保湿剤、増粘剤、香料、色素等を本発明の効果
を損なわない範囲で適宜配合することができる。In addition to propolis extract, the external skin preparation of the present invention contains sulfur, hinokitiol, triclosan, trichlorocarbanilide, chlorhexidine hydrochloride, chlorhexidine gluconate, halocarpan, chlorophenesine, benzethonium chloride, benzalkonium chloride, Antibacterial agents such as lysozyme, alkyldiaminoethylglycine hydrochloride, isopropylmethylphenol, benzoic acid, Photosensor No. 201, thymol, hexachlorophene, berberine, thioxolone, vitamins such as vitamin AlB2, B6, E5 biotin, nicotinic acid, and salicylic acid. , exfoliating agents such as resorcin, clycyrrhetinic acid, glycyrrhizic acid, allantoin, epsilon aminocaproic acid, butyl flufenamate, azulene, camphor, zinc chloride, zinc white, menthol, indomethacin, ibuprofen piconol, mefenamic acid, and their derivatives. Anti-inflammatory agents, zinc and its compounds, lactic acid, and oils, surfactants, water, ethanol, humectants, thickeners, fragrances, pigments, etc. may be added as appropriate to the extent that they do not impair the effects of the present invention, although they vary depending on the properties. Can be blended.
本発明の皮脂抑制剤の性状は、クリーム、軟膏、ローシ
ョン等外皮に適用できる性状のものであればいずれでも
良い。The sebum suppressant of the present invention may be in any form as long as it can be applied to the outer skin, such as a cream, ointment, or lotion.
[発明の効果]
本発明のプロポリス抽出物は非常に良好な可逆的、局所
的皮脂抑制効果を示す。またこの化合物は非常に良く皮
膚に浸透し、全く刺激を与えないので、特に脂漏性疾患
の治療に適する。この活性は特異的に皮脂に向けられ、
それら以外の器官に全く影響しない。[Effects of the Invention] The propolis extract of the present invention exhibits a very good reversible and local sebum suppressing effect. The compound also penetrates the skin very well and is completely non-irritating, making it particularly suitable for the treatment of seborrheic diseases. This activity is specifically directed towards sebum,
It has no effect on any other organs.
(以下余白)
[実施例]
実施例1 化粧水
1)ソルビトール(70%) 3.
0g2)グリセリン 5.
0g3)水 70.0
g4)塩酸ピリドキシン 0.5
g5)プロポリス抽出物 1・0
g6)ポリオキシエチレン(以下、POEという)硬化
ヒマシ油誘導体 0.5g7)エタノール
20.0g8)香料
適量1)2)3)4)の成分を混
合溶解し、これに、5)6)7)8)の混合溶液を攪拌
しながら加えて均一な溶液として化粧水を得る。(Margin below) [Example] Example 1 Lotion 1) Sorbitol (70%) 3.
0g2) Glycerin 5.
0g3) Water 70.0
g4) Pyridoxine hydrochloride 0.5
g5) Propolis extract 1.0
g6) Polyoxyethylene (hereinafter referred to as POE) hydrogenated castor oil derivative 0.5g7) Ethanol
20.0g8) Fragrance
Mix and dissolve appropriate amounts of the ingredients 1), 2), 3), and 4), and add the mixed solution of 5), 6), 7), and 8) with stirring to obtain a lotion as a uniform solution.
実施例2 化粧水
1)ソルビトール(70%)3.0g
2)グリセリン 5.0g3
)水 70.5g4)
グリチルリチン酸 0.5g5)プ
ロポリス抽出物 0.5g6)
P OE硬化ヒマシ油誘導体 0.5g7)
エタノール 20・0g8)
香料 適量1)2)3
)4)の成分を混合溶解し、これに、5)6)?)8)
の混合溶液を攪拌しながら加えて均一な溶液として化粧
水を得る。Example 2 Lotion 1) Sorbitol (70%) 3.0g 2) Glycerin 5.0g3
) Water 70.5g4)
Glycyrrhizic acid 0.5g5) Propolis extract 0.5g6)
P OE hydrogenated castor oil derivative 0.5g7)
Ethanol 20.0g8)
Fragrance Appropriate amount 1) 2) 3
) Mix and dissolve the ingredients in 4) and add to this 5) 6)? )8)
Add the mixed solution while stirring to obtain a lotion as a homogeneous solution.
実施例3 乳液
1)セタノール 1・5g
2)ステアリン酸 1.0g
3)パルミチン酸 0.5g
4)液状ラノリン 1.0g
5)スクワラン 2・0g6
)ミリスチン酸イソプロピル 1.0g7
)モノステアリン酸グリセリル 1.5g8)
ツウイーン20 0.5g9
)ベルベリン 0・5g10
)プロピレングリコール 3.0g11
)ポリエチレングリコール400 2.0 g
l2)トリエタノールアミン 1.0g
13)プロポリス抽出液(乾燥残部) 2.0
g14)精製水 82・5
g1)〜9)の各成分を混合して混合物を得た。別に、
10)〜14)の成分を混合して混合物を得た。それぞ
れの混合物を別々に70℃に加熱溶解後、乳化機により
混合乳化したのち、熱交換冷却して乳液をえた。Example 3 Emulsion 1) Setanol 1.5g
2) Stearic acid 1.0g
3) Palmitic acid 0.5g
4) Liquid lanolin 1.0g
5) Squalane 2.0g6
) Isopropyl myristate 1.0g7
) Glyceryl monostearate 1.5g8)
Tween 20 0.5g9
) Berberine 0.5g10
) Propylene glycol 3.0g11
) Polyethylene glycol 400 2.0 g
l2) Triethanolamine 1.0g
13) Propolis extract (dry residue) 2.0
g14) Purified water 82.5
Each component of g1) to 9) was mixed to obtain a mixture. Separately,
Components 10) to 14) were mixed to obtain a mixture. Each mixture was separately heated and dissolved at 70°C, mixed and emulsified using an emulsifier, and then cooled by heat exchange to obtain an emulsion.
実施例4 クリーム
1)ミツロウ 11・0g
2)パラフィンワックス 6.0g
3)ラノリン 3・0g
4)イソプロピルミリステート6.0g5)スクワラン
8・0g6)流動パラフ
ィン 27・5g7)プロポリス
抽出物 1.5g8)アラントイ
ン 0.5g9) P OE
ソルビタンモノステアレート1.5g10)ソルビタン
モノステアレート4.0g11)防腐剤
適量12)プロピレングリコール
2.0g13)ホウ砂
1・0g14)水
28.0 gl)2)3)4)5)6)7)
8)9)10)11)12)の成分を混合し、約75℃
で加熱し溶解し、これに約75℃で、加熱した13)1
4)の混合液を攪拌しながら加え、冷却し、55℃で香
料を適量加え、45℃まで攪拌をつづけ、放置してクリ
ームを得る。Example 4 Cream 1) Beeswax 11.0g
2) Paraffin wax 6.0g
3) Lanolin 3.0g
4) Isopropyl myristate 6.0g5) Squalane 8.0g6) Liquid paraffin 27.5g7) Propolis extract 1.5g8) Allantoin 0.5g9) P OE
Sorbitan monostearate 1.5g10) Sorbitan monostearate 4.0g11) Preservative
Appropriate amount 12) Propylene glycol
2.0g13) Borax
1.0g14) Water
28.0 gl)2)3)4)5)6)7)
8) Mix the ingredients of 9) 10) 11) and 12) and heat at about 75°C.
13) 1.
Add the mixture of 4) while stirring, cool, add an appropriate amount of fragrance at 55°C, continue stirring until 45°C, and leave to obtain a cream.
実施例5 軟膏
1)固体パラフィン 10゜0g
2)ピースワックス 10.0g
3)スクワラン 10・0g
4)プロポリス抽出物 1.0g
5)レゾルシン 0・1g
6)亜鉛華 0・5g7
)香料 適量8)ワセ
リン 68・4g上記成
分を混合し、混合物を80℃に加熱溶解した後、攪拌冷
却を行い、軟膏を得た。Example 5 Ointment 1) Solid paraffin 10°0g
2) Peace wax 10.0g
3) Squalane 10.0g
4) Propolis extract 1.0g
5) Resorcinol 0.1g
6) Zinc white 0.5g7
) Perfume Appropriate amount 8) Vaseline 68.4 g The above ingredients were mixed, the mixture was heated and dissolved at 80° C., and then cooled with stirring to obtain an ointment.
実施例6 ヘアトニック
1)エタノール 51・5g
2)ヒノキチオール 0.3g
3)ビタミンE 0.5
g4)ニラコールHCO−601,0g
5)香料 適量6)プ
ロポリス抽出物 0.7g7)精
製水 45.0g8)グ
リセリン 1・0g9)色素
適量1 )3) 3
)4) 5)を室温下、溶解してアルコール相を得た。Example 6 Hair tonic 1) Ethanol 51.5g
2) Hinokitiol 0.3g
3) Vitamin E 0.5
g4) Niracol HCO-60 1.0g 5) Fragrance Appropriate amount6) Propolis extract 0.7g7) Purified water 45.0g8) Glycerin 1.0g9) Pigment Appropriate amount1) 3) 3
)4) and 5) were dissolved at room temperature to obtain an alcohol phase.
6)?) 8)9)の混合液を加熱下に溶解し冷却し水
相を得た。水相に前記アルコール相を加え可溶化してヘ
アトニックを得た。6)? ) The mixed liquid of 8) and 9) was dissolved under heating and cooled to obtain an aqueous phase. The alcohol phase was added to the aqueous phase and solubilized to obtain a hair tonic.
次に臨床例をあげて本発明の効果を更に詳細に説明する
。Next, the effects of the present invention will be explained in more detail by giving clinical examples.
(使用薬剤)
下記処方、製造法で得たローションタイプの皮膚外用剤
を使用した。(Medicine used) A lotion-type skin external preparation obtained by the following formulation and manufacturing method was used.
1)プロポリス抽出物 1.0g2
) P OE (60モル)硬化ヒマシ油 2
.0g3)グリセリン 10・
0g4)ジプロピレングリコール 10.0
g5)113−ブチレングリコール 5.0g6
)ポリエチレングリコール1500 5.0 g
7)セチルイソオフタネ−) 10.0g
8)スクワラン 5.0g9
)メチルパラベン 1・0g10
)カルボキシビニルポリマー 0.3g11)
へキサメタリン酸ソーダ 0.08g12)
イオン交換水 11..0g13
)水酸化カリウム 0・12g14
)イオン交換水 39.5g1)2
)3)4)5)6)を60℃で加熱溶解する。これに7
)8)9)を同じ<60℃に加熱溶解したものを添加混
合し、ホモミキサーで処理をしてゲルを作る。次にこの
ゲルに10)11)を、12)に溶解せしめたものを徐
添加しホモミキサーで分散した後、13)を14)に溶
解したものを添加混合し、ホモミキサーで乳化してロー
ションタイプの皮膚外用剤を得た。1) Propolis extract 1.0g2
) P OE (60 mol) Hydrogenated castor oil 2
.. 0g3) Glycerin 10・
0g4) Dipropylene glycol 10.0
g5) 113-butylene glycol 5.0g6
) Polyethylene glycol 1500 5.0 g
7) Cetyl isophutane) 10.0g
8) Squalane 5.0g9
) Methylparaben 1.0g10
) Carboxyvinyl polymer 0.3g11)
Sodium hexametaphosphate 0.08g12)
Ion exchange water 11. .. 0g13
) Potassium hydroxide 0.12g14
) Ion exchange water 39.5g1)2
) 3) 4) 5) 6) are heated and dissolved at 60°C. 7 for this
) Add and mix 8) and 9) heated and dissolved at <60°C, and process with a homomixer to make a gel. Next, 10) and 11) dissolved in 12) were gradually added to this gel and dispersed with a homomixer, then 13) dissolved in 14) was added and mixed, and emulsified with a homomixer to form a lotion. A type of external preparation for skin was obtained.
(使用対象および観察期間)
15〜30歳までの脂漏性皮膚炎の患者20名に4週間
使用させた。(Targets for Use and Observation Period) The product was used for 4 weeks by 20 patients with seborrheic dermatitis between the ages of 15 and 30.
(使用方法)
化粧石鹸を用いて顔面をよく洗浄した後、皮脂の上にの
み、前記したローションタイプの皮膚外用剤を1日に1
〜3回塗布せしめた。(How to use) After thoroughly washing your face with soap, apply the above-mentioned lotion-type skin preparation once a day only on the sebum.
It was applied ~3 times.
(皮脂の測定)
使用前と4週間使用後の総皮脂量をガラスカップ法で皮
脂を採取して重量法[Ohokawa、H,、et a
l、。(Measurement of sebum) The total amount of sebum before use and after 4 weeks of use was measured by collecting sebum using the glass cup method and using the gravimetric method [Ohokawa, H., et al.
l.
Anal、Biochem、、95.351358(1
979)]にて測定した。Anal, Biochem, 95.351358 (1
979)].
皮脂量は以下の式のごとく相対比で表した。The amount of sebum was expressed as a relative ratio as shown in the following formula.
使用前の総皮脂量
(以下余白)
(結果)
症例番号 年令 性 皮脂減少率
1 20 女 10
2 21 女 11
3 23 女 10
4 23 男 8
5 17 女 6
6 20 男 10
7 15 女 15
8 29 女 12
9 30 男 4
10 18 女 8
11 21 女 8
12 24 女 3
13 24 女 7
症例番号 年令 性 皮脂減少率
14 26 男 915 2
5 女 6
16 25 男 5
17 28 女 2
18 26 女 4
19 22 男 5
20 25 女 2
男6名、女14名計20名の臨床テスト結果、平均皮脂
減少率は7.3%であり、本発明の皮膚外用剤剤の効果
が立証された。Total sebum amount before use (blank below) (Results) Case number Age Gender Sebum reduction rate 1 20 Female 10 2 21 Female 11 3 23 Female 10 4 23 Male 8 5 17 Female 6 6 20 Male 10 7 15 Female 15 8 29 Female 12 9 30 Male 4 10 18 Female 8 11 21 Female 8 12 24 Female 3 13 24 Female 7 Case number Age Sex Sebum reduction rate 14 26 Male 915 2
5 Female 6 16 25 Male 5 17 28 Female 2 18 26 Female 4 19 22 Male 5 20 25 Female 2 Results of clinical tests on 20 people, 6 males and 14 females, showed that the average sebum reduction rate was 7.3%. The effectiveness of the skin external preparation of the present invention was demonstrated.
Claims (1)
徴とする皮脂抑制効果を有する皮膚外用剤。A skin preparation for external use that has a sebum suppressing effect and is characterized by containing an extract of propolis as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62013062A JPS63179812A (en) | 1987-01-22 | 1987-01-22 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62013062A JPS63179812A (en) | 1987-01-22 | 1987-01-22 | External preparation for skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63179812A true JPS63179812A (en) | 1988-07-23 |
Family
ID=11822649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62013062A Pending JPS63179812A (en) | 1987-01-22 | 1987-01-22 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63179812A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0529962A3 (en) * | 1991-08-27 | 1994-01-26 | Hayashibara Biochem Lab | |
JPH10194923A (en) * | 1997-01-13 | 1998-07-28 | Nippon Zetotsuku Kk | Emulsified composition |
WO1998029085A3 (en) * | 1996-12-31 | 1999-04-22 | American Med Res Llc | Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties |
JP2002087972A (en) * | 2000-09-18 | 2002-03-27 | Biomedeikusu:Kk | Method for solubilizing extracted solution of propolis into water and water-soluble propolis composition |
DE20306600U1 (en) * | 2003-04-29 | 2003-09-04 | Karpfl Vera | Pharmaceutical product, useful for skin or wound care, comprises an ointment base containing a tincture of poplar bud resin combined with milk fat or another carrier |
US6645510B1 (en) | 1998-06-30 | 2003-11-11 | American Medical Research, Inc. | Method of treating topical ailments |
WO2011000218A1 (en) * | 2009-06-30 | 2011-01-06 | Shuen-Lu Huang | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
CN104306679A (en) * | 2014-11-18 | 2015-01-28 | 郝建友 | Chinese herb agentia for treating epidemic cerebrospinal meningitis and preparation method thereof |
-
1987
- 1987-01-22 JP JP62013062A patent/JPS63179812A/en active Pending
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0529962A3 (en) * | 1991-08-27 | 1994-01-26 | Hayashibara Biochem Lab | |
KR100233026B1 (en) * | 1991-08-27 | 2000-02-01 | 도시오 미야께 | Purified propolis-extract and its preparation and uses |
WO1998029085A3 (en) * | 1996-12-31 | 1999-04-22 | American Med Res Llc | Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties |
JPH10194923A (en) * | 1997-01-13 | 1998-07-28 | Nippon Zetotsuku Kk | Emulsified composition |
US6645510B1 (en) | 1998-06-30 | 2003-11-11 | American Medical Research, Inc. | Method of treating topical ailments |
JP2002087972A (en) * | 2000-09-18 | 2002-03-27 | Biomedeikusu:Kk | Method for solubilizing extracted solution of propolis into water and water-soluble propolis composition |
DE20306600U1 (en) * | 2003-04-29 | 2003-09-04 | Karpfl Vera | Pharmaceutical product, useful for skin or wound care, comprises an ointment base containing a tincture of poplar bud resin combined with milk fat or another carrier |
WO2011000218A1 (en) * | 2009-06-30 | 2011-01-06 | Shuen-Lu Huang | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
CN102481290A (en) * | 2009-06-30 | 2012-05-30 | 德安生医有限公司 | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
US9486402B2 (en) | 2009-06-30 | 2016-11-08 | Derman Biomedicine Co. Ltd | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
CN104306679A (en) * | 2014-11-18 | 2015-01-28 | 郝建友 | Chinese herb agentia for treating epidemic cerebrospinal meningitis and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH03190809A (en) | Skin external preparation | |
JPH03220129A (en) | Sebum suppressant | |
CN112587446A (en) | Composition for treating acne and preparation method and application thereof | |
JP3223404B2 (en) | Hair restorer | |
JP2878353B2 (en) | External preparation for skin | |
WO2018070706A1 (en) | Composition for preventing hair loss or promoting hair growth comprising decanal or pharmaceutically acceptable salt thereof as active ingredient | |
JPS63179812A (en) | External preparation for skin | |
JPS6360910A (en) | Skin drug for external use | |
JP4469617B2 (en) | Hair restoration | |
JP2696523B2 (en) | Anti-dandruff agent and hair cosmetic | |
JPS6322510A (en) | External preparation for skin | |
JPH03209309A (en) | Alopecia-preventing agent | |
JPS6360935A (en) | Sebum suppressive agent | |
JP2012506851A (en) | Topical depigmenting composition and use thereof | |
JPS6360909A (en) | Skin drug for external use | |
KR20040056079A (en) | Cosmetic composition for preventing and therapeutic for a pimple | |
JPH11302147A (en) | Cosmetic | |
JPH01290614A (en) | Sebum secretion promoter | |
JP3542700B2 (en) | Head composition | |
JPS6322506A (en) | External preparation for skin | |
JP2005200357A (en) | Hair-fostering cosmetic | |
US9556138B2 (en) | Method of treatment for acne and an anti-acne formulation | |
RU2139035C1 (en) | Dentifrice water | |
JPS6360908A (en) | Skin drug for external use | |
JPH07149614A (en) | Hair tonic agent |